CD38 Monoclonal Antibodies for Early Relapsed Multiple Myeloma and the Risk of COVID Infection

Author(s):

The panel discusses the strategies for reducing or preventing COVID infection in patients being treated for early relapse multiple myeloma with CD38 monoclonal antibodies.

EP: 1.Data Updates in the Frontline Treatment of Patients With Transplant-Eligible Multiple Myeloma

EP: 2.Considerations for Frontline Treatment in Transplant-Ineligible Multiple Myeloma

EP: 3.Defining Frailty in Multiple Myeloma for Optimal Treatment

EP: 4.Approaches to Treatment Duration in Newly-Diagnosed Multiple Myeloma

EP: 5.Relapse in Multiple Myeloma: Biochemical and Chemical

EP: 6.Data Updates in the Treatment of Relapsed Multiple Myeloma

EP: 7.Strategies for Treatment of Multiple Myeloma at Late Relapse

EP: 8.Quadruplet Combination Therapies in Relapsed Multiple Myeloma

EP: 9.Considerations for Treatment Decision-Making in Early-Relapse Multiple Myeloma

Now Viewing

CD38 Monoclonal Antibodies for Early Relapsed Multiple Myeloma and the Risk of COVID Infection

EP: 1.Data Updates in the Frontline Treatment of Patients With Transplant-Eligible Multiple Myeloma

EP: 2.Considerations for Frontline Treatment in Transplant-Ineligible Multiple Myeloma

EP: 3.Defining Frailty in Multiple Myeloma for Optimal Treatment

EP: 4.Approaches to Treatment Duration in Newly-Diagnosed Multiple Myeloma

EP: 5.Relapse in Multiple Myeloma: Biochemical and Chemical

EP: 6.Data Updates in the Treatment of Relapsed Multiple Myeloma

EP: 7.Strategies for Treatment of Multiple Myeloma at Late Relapse

EP: 8.Quadruplet Combination Therapies in Relapsed Multiple Myeloma

EP: 9.Considerations for Treatment Decision-Making in Early-Relapse Multiple Myeloma

EP: 10.CD38 Monoclonal Antibodies for Early Relapsed Multiple Myeloma and the Risk of COVID Infection

EP: 11.BCMA-Targeting Bispecifics in Relapsed/Refractory Multiple Myeloma

EP: 12.Retreatment with a BCMA-Targeting Bispecific for R/R MM

EP: 13.Data Updates on Immunotherapy Combinations in Multiple Myeloma

EP: 14.Targets in Multiple Myeloma: GPRC5D

EP: 15.Targets in Multiple Myeloma: FcRH5

EP: 16.Managing Cytokine Release Syndrome and Immune Effector Cell-Associated Neurotoxicity Syndrome in Multiple Myeloma

EP: 17.Preventing Infection in Patients with Multiple Myeloma During Treatment

EP: 18.Does Belantamab Have a Place in Multiple Myeloma Treatment?

EP: 19.Unmet Needs and Future Perspectives in Multiple Myeloma Care

Latest Conference Coverage